Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsGlobeNewsWire • 03/28/24
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionGlobeNewsWire • 03/25/24
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanGlobeNewsWire • 03/21/24
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookGlobeNewsWire • 01/04/24
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceGlobeNewsWire • 11/29/23
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsGlobeNewsWire • 11/09/23
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 11/09/23
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationGlobeNewsWire • 11/02/23
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerGlobeNewsWire • 10/23/23
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual MeetingGlobeNewsWire • 10/13/23
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of DirectorsGlobeNewsWire • 10/02/23
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a HumanGlobeNewsWire • 09/25/23
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/20/23
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsGlobeNewsWire • 09/11/23
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney TransplantationGlobeNewsWire • 09/05/23
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial ResultsGlobeNewsWire • 08/10/23
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of NephrologyGlobeNewsWire • 03/31/23
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial ResultsGlobeNewsWire • 03/30/23
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023GlobeNewsWire • 03/23/23